Enumeral’s lead humanized anti-PD-1 antibodies demonstrated high levels of T-cell activation in ex vivo human immune cell assays and anti-tumor activity in in vivo studies
CAMBRIDGE, MA, USA I January 8, 2016 I Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced the presentation of research findings for the Company’s novel class of anti-PD-1 antibodies at the Function of the Tumor Microenvironment in Cancer Progression Conference, sponsored by the American Association for Cancer Research (AACR) and taking place in San Diego, CA, from January 7-10, 2016. Enumeral is advancing a novel class of potentially allosteric anti-PD-1 antibodies with distinctive properties compared to currently marketed anti-PD-1 antagonists, including a mechanism of action that does not appear to require the disruption of PD-1 interaction with PD-L1.
Enumeral is reporting in a poster presentation at the AACR conference that Enumeral’s anti-PD-1 antibodies can reverse T cell suppression in ex vivo assays by eliciting high levels of T-cell activation as measured by increased secretion of effector cytokines such as interferon gamma and increases in expression of the IL-2 receptor alpha chain, CD25. Further, in an in vivo preclinical model harboring a reconstituted human immune system, Enumeral’s fully humanized anti-PD-1 antibodies exhibited significant anti-tumor efficacy against a human lung adenocarcinoma xenograft.
In addition, Enumeral is presenting a second poster at the AACR conference detailing how Enumeral’s proprietary single-cell immune profiling technology was used to match T cell receptor alpha and beta (TCRα and TCRβ) pair sequences from specified T cells isolated from the tumor of a metastatic melanoma patient and uniquely link them to their functional profiles. In this method, researchers first identified a subset of T cells of interest based on their functional profiles, including surface markers and secreted cytokines, and then isolated each individual T cell for TCR sequencing. Results presented demonstrated this method can be applied to T cells from both blood and solid tissues, enabling the identification of rare or expanded T cell clones.
Enumeral Abstracts at AACR’s 2016 Tumor Microenvironment Special Conference
“Determination of expressed T cell receptor sequences of single human T cells isolated after functional profiling.” Abstract #A14; Poster Session A: Tumor Immunity and Therapies; Thursday, January 7, 2016, from 7:30-9:30 PM Pacific Time.
“Discovery and functional characterization of novel anti-PD-1 antibodies using ex vivo cell-based assays, single-cell immunoprofiling, and in vivo studies in humanized mice.” Abstract #B30; Poster Session B; Friday, January 8, 2016, from 4:00-6:00 PM Pacific Time.
About Enumeral
Enumeral is a biopharmaceutical company discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases. The Company is building a pipeline focused on next-generation checkpoint modulators, with initial targets including PD-1, TIM-3, LAG-3, TIGIT, VISTA, and others. In developing these agents, Enumeral’s researchers apply a proprietary immune profiling technology platform that measures functioning of the human immune system at the level of individual cells, providing key insights for candidate selection and validation. For more information on Enumeral, please visit www.enumeral.com.
SOURCE: Enumeral
Post Views: 61
Enumeral’s lead humanized anti-PD-1 antibodies demonstrated high levels of T-cell activation in ex vivo human immune cell assays and anti-tumor activity in in vivo studies
CAMBRIDGE, MA, USA I January 8, 2016 I Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced the presentation of research findings for the Company’s novel class of anti-PD-1 antibodies at the Function of the Tumor Microenvironment in Cancer Progression Conference, sponsored by the American Association for Cancer Research (AACR) and taking place in San Diego, CA, from January 7-10, 2016. Enumeral is advancing a novel class of potentially allosteric anti-PD-1 antibodies with distinctive properties compared to currently marketed anti-PD-1 antagonists, including a mechanism of action that does not appear to require the disruption of PD-1 interaction with PD-L1.
Enumeral is reporting in a poster presentation at the AACR conference that Enumeral’s anti-PD-1 antibodies can reverse T cell suppression in ex vivo assays by eliciting high levels of T-cell activation as measured by increased secretion of effector cytokines such as interferon gamma and increases in expression of the IL-2 receptor alpha chain, CD25. Further, in an in vivo preclinical model harboring a reconstituted human immune system, Enumeral’s fully humanized anti-PD-1 antibodies exhibited significant anti-tumor efficacy against a human lung adenocarcinoma xenograft.
In addition, Enumeral is presenting a second poster at the AACR conference detailing how Enumeral’s proprietary single-cell immune profiling technology was used to match T cell receptor alpha and beta (TCRα and TCRβ) pair sequences from specified T cells isolated from the tumor of a metastatic melanoma patient and uniquely link them to their functional profiles. In this method, researchers first identified a subset of T cells of interest based on their functional profiles, including surface markers and secreted cytokines, and then isolated each individual T cell for TCR sequencing. Results presented demonstrated this method can be applied to T cells from both blood and solid tissues, enabling the identification of rare or expanded T cell clones.
Enumeral Abstracts at AACR’s 2016 Tumor Microenvironment Special Conference
“Determination of expressed T cell receptor sequences of single human T cells isolated after functional profiling.” Abstract #A14; Poster Session A: Tumor Immunity and Therapies; Thursday, January 7, 2016, from 7:30-9:30 PM Pacific Time.
“Discovery and functional characterization of novel anti-PD-1 antibodies using ex vivo cell-based assays, single-cell immunoprofiling, and in vivo studies in humanized mice.” Abstract #B30; Poster Session B; Friday, January 8, 2016, from 4:00-6:00 PM Pacific Time.
About Enumeral
Enumeral is a biopharmaceutical company discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases. The Company is building a pipeline focused on next-generation checkpoint modulators, with initial targets including PD-1, TIM-3, LAG-3, TIGIT, VISTA, and others. In developing these agents, Enumeral’s researchers apply a proprietary immune profiling technology platform that measures functioning of the human immune system at the level of individual cells, providing key insights for candidate selection and validation. For more information on Enumeral, please visit www.enumeral.com.
SOURCE: Enumeral
Post Views: 61
